Modifying and personalizing prostate cancer screening

Alexandra Stone, Hanan Goldberg^

Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA

Correspondence to: Hanan Goldberg, MD, MSc. Assistant Professor, Department of Urology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. Email: gohanan@gmail.com.

Comment on: Remmers S, Bangma CH, Godtman RA, *et al.* Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2023;84:503-9.

The use of prostate-specific antigen (PSA) as a marker for prostate cancer (PCa) screening has been widely debated in literature. Some research argues that in the era of utilizing PSA as a marker for PCa, mortality rates have decreased significantly, implicating its importance in the field (1). However, opposing research indicates the use of PSA is insignificant in the overall effect on mortality, causing more secondary harmful effects than actual benefits from screening (2).

The recent publication by Remmers *et al.* aims to uncover this discrepancy. In this study, the authors evaluated more than 50,000 men between the ages of 55–69 years old who participated in the PCa screening trial—The European Randomized Study of Screening for PCa (ERSPC) (3). The authors specifically assessed the actuarial probability for PCa and for clinically significant PCa (csPCa). The authors concluded that a patient's baseline PSA level at certain age groups is associated with the risk of developing PCa. If a baseline PSA was measured <1.0 ng/mL between ages 55–69 years old, the actuarial probability of developing PCa at 16-year follow-up was shown to be 2.7% and csPCa was 1.3%. The authors stated that this was low enough to suggest no further screening is needed.

The number of men between ages 55–59 years old with a PSA <1.0 ng/mL was 12,825 (50%). For men between the ages of 60–64 years old, 6,579 men (39%) were found to have a PSA <1.0 ng/mL. A total of 4,209 men (33%) between the ages of 65–69 years old were found to have a

PSA <1.0 ng/mL. The authors showed that the actuarial probabilities at 16-year follow-up of developing csPCa for these men with a PSA <1 ng/mL ranged from 1.2–1.5% [95% confidence interval (CI)] and no greater than 3% for any PCa, indicating that this PSA level is acceptable for not recommending additional screening.

Another study, the population-based cohort study conducted by Carlsson *et al.* (4), examined 1,756 men aged 60 years old participating in either the screening trial in Gothenburg or in the Malmo Preventive Project. The authors showed very similar results that for men with a PSA <1 ng/mL no further screening is recommended, while for men with a PSA >2 ng/mL, screening should continue. The results of this study are also similar with the study by Preston *et al.* showing that baseline PSA among men aged 40–59 years old could predict PCa specific mortality (5).

In the Remmers study, it was also shown that in men with a PSA <1 ng/mL who were eventually diagnosed with PCa, the median time from screening to diagnosis was 12 years while the median time from diagnosis to death was 1.7 years (3). We agree with the authors that the screening algorithm needs to be improved, and that this should not include lowering the PSA threshold for a prostate biopsy, due to obvious reasons of over diagnosis and overtreatment. Additionally, PSA levels can vary, and there is evidence that lifestyle factors such as sugar-rich diets, long-term aspirin use, and smoking can impact PSA concentrations, affecting its accuracy as a screening tool (6-8). Therefore, relying

^ ORCID: 0000-0002-5777-2138.

Transl Androl Urol 2024;13(5):899-901 | https://dx.doi.org/10.21037/tau-23-612

solely on PSA levels is probably not sufficient, and other factors should be incorporated into the screening algorithm. The contemporary screening and diagnosis protocol utilized in modern healthcare is already substantially different than the one used in this study. Currently, we are already aware that the consideration of a patient's biological rather than his chronological age is important. We also know that a man's access to healthcare, prostate volume, his race and family cancer history, are impactful as well. Lastly, the growing use of pre-biopsy prostate magnetic resonance imaging (MRI), and adoption of various molecular testing, has literally changed the game and has impacted screening (9-11). Indeed, risk-adapted screening with incorporation of prostate MRI, is more appropriate, as shown in the PROBASE trial (12).

We commend the authors for publishing this trial and understand that this is a rapidly changing field, where risk adapted PCa screening is more appropriate for going forward. Screening needs to be tailored for each patient, considering various biological, genetic, and social parameters. Additionally, it would need to incorporate anatomical-based testing such as multiparametric MRI and perhaps include molecular/genetic testing in the future, as needed.

Acknowledgments

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Translational Andrology and Urology*. The article has undergone external peer review.

Peer Review File: Available at https://tau.amegroups.com/article/view/10.21037/tau-23-612/prf

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-612/coif). H.G. is a speaker for Bayer and Pfizer. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Catalona WJ. Prostate Cancer Screening. Med Clin North Am 2018;102:199-214.

2. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519.

3. Remmers S, Bangma CH, Godtman RA, et al. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2023;84:503-9.

4. Carlsson S, Assel M, Sjoberg D, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 2014;348:g2296.

5. Preston MA, Batista JL, Wilson KM, et al. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 2016;34:2705-11.

6. Liu Z, Chen C, Yu F, et al. Association of Total Dietary Intake of Sugars with Prostate-Specific Antigen (PSA) Concentrations: Evidence from the National Health and Nutrition Examination Survey (NHANES), 2003-2010. Biomed Res Int 2021;2021:4140767.

7. Mantica G, Chierigo F, Cassim F, et al. Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study. Res Rep Urol 2022;14:369-77.

8. De Nunzio C, Tema G, Trucchi A, et al. Smoking reduces PSA accuracy for detection of prostate cancer: results from an Italian cross-sectional study. Minerva Urol Nefrol 2019;71:583-9.

9. Nair SS, Chakravarty D, Dovey ZS, et al. Why do African-American men face higher risks for lethal prostate cancer? Curr Opin Urol 2022;32:96-101.

10. Zheng G, Sundquist J, Sundquist K, et al. Prostate cancer

incidence and survival in relation to prostate cancer as second cancer in relatives. Cancer Med 2022;11:2117-24.

11. Zou Q, Cao J, Chen Z, et al. Prostate Volume is A Predictor of Gleason Score Upgrading after Radical Prostatectomy in Low-Risk Prostate Cancer: A Systematic Review and Meta-analysis. Urol J 2024;21:20-8.

12. Arsov C, Albers P, Herkommer K, et al. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer 2022;150:1861-9.